OOIR: Observatory of International Research

Papers

(The TQCC of Journal of the American College of Cardiology is 0. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-11-01 to 2024-11-01.)

Article	Citations
Global Burden of Cardiovascular Diseases and Risk Factors, 1990–2019	5561
2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure	1082
2020 ACC/AHA Guideline for the Management of Patients With Valvular Heart Disease	969
2021 ACC/AHA/SCAI Guideline for Coronary Artery Revascularization	710
The Global Burden of Cardiovascular Diseases and Risk	668
2021 Update to the 2017 ACC Expert Consensus Decision Pathway for Optimization of Heart Failure Treatment: Answers to 10 Pivotal Issues About Heart Failure With Reduced Ejection Fraction	627
2020 ACC/AHA Guideline for the Management of Patients With Valvular Heart Disease: Executive Summary	621
STS-ACC TVT Registry of Transcatheter Aortic Valve Replacement	588
Valve Academic Research Consortium 3: Updated Endpoint Definitions for Aortic Valve Clinical Research	536
2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy	424
2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: Executive Summary	414
2021 AHA/ACC/ASE/CHEST/SAEM/SCCT/SCMR Guideline for the Evaluation and Diagnosis of Chest Pain	409
The Global Burden of Cardiovascular Diseases and Risks	347
Randomized Trial of Empagliflozin in Nondiabetic Patients With Heart Failure and Reduced Ejection Fraction	308
Characterization of Myocardial Injury in Patients With COVID-19	306
SCAI SHOCK Stage Classification Expert Consensus Update: A Review and Incorporation of Validation Studies	303
Interpreting the Kansas City Cardiomyopathy Questionnaire in Clinical Trials and Clinical Care	294
Remnant Cholesterol, Not LDL Cholesterol, Is Associated With Incident Cardiovascular Disease	292
Transcatheter Edge-to-Edge Repair for Treatment of Tricuspid Regurgitation	283
Coronary Microvascular Dysfunction Across the Spectrum of Cardiovascular Diseases	276
The ARIC (Atherosclerosis Risk In Communities) Study	261
2022 ACC Expert Consensus Decision Pathway on Cardiovascular Sequelae of COVID-19 in Adults: Myocarditis and Other Myocardial Involvement, Post-Acute Sequelae of SARS-CoV-2 Infection, and Return to Pl	250
Intravascular Lithotripsy for Treatment of Severely Calcified Coronary Artery Disease	235
Registry of Arterial and Venous Thromboembolic Complications in Patients With COVID-19	227
Strain-Guided Management of Potentially Cardiotoxic Cancer Therapy	227

Outcomes 2 Years After Transcatheter Aortic Valve Replacement in Patients at Low Surgical Risk	224
Machine Learning and the Future of Cardiovascular Care	223
Diagnosis and Evaluation of Hypertrophic Cardiomyopathy	219
Prevalence and Outcomes of Concomitant Aortic Stenosis and Cardiac Amyloidosis	215
Randomized Trial of Interleukin-6 Receptor Inhibition in Patients With Acute ST-Segment Elevation Myocardial Infarction	215
2022 ACC Expert Consensus Decision Pathway on the Role of Nonstatin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk	213
Global Burden of Cardiovascular Diseases and Risks, 1990-2022	196
2021 ACC/AHA/SCAI Guideline for Coronary Artery Revascularization: Executive Summary	186
Apolipoprotein B and Non-HDL Cholesterol Better Reflect Residual Risk Than LDL Cholesterol in Statin-Treated Patients	184
Pathological Evidence for SARS-CoV-2 as a Cause of Myocarditis	182
2020 ACC Expert Consensus Decision Pathway for Anticoagulant and Antiplatelet Therapy in Patients With Atrial Fibrillation or Venous Thromboembolism Undergoing Percutaneous Coronary Intervention or Wi	176
2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy: Executive Summary	175
Management of Hypertrophic Cardiomyopathy	174
2022 ACC/AHA Guideline for the Diagnosis and Management of Aortic Disease	174
2023 ACC Expert Consensus Decision Pathway on Comprehensive Multidisciplinary Care for the Patient With Cardiac Amyloidosis	172
Randomized Trial of Left Bundle Branch vs Biventricular Pacing for Cardiac Resynchronization Therapy	172
Inflammation, Aging, and Cardiovascular Disease	172
2021 ACC Expert Consensus Decision Pathway on the Management of ASCVD Risk Reduction in Patients With Persistent Hypertriglyceridemia	171
Myosin Inhibition in Patients With Obstructive Hypertrophic Cardiomyopathy Referred for Septal Reduction Therapy	170
Interventions for Frailty Among Older Adults With Cardiovascular Disease	167
Impact of Plaque Burden Versus Stenosis on Ischemic Events in Patients With Coronary Atherosclerosis	166
Prognostic Impact of Prior Heart Failure in Patients Hospitalized With COVID-19	163
Cardiovascular Deaths During the COVID-19 Pandemic in the United States	162
Feasibility Study of the Transcatheter Valve Repair System for Severe Tricuspid Regurgitation	161
Pathophysiology of Takotsubo Syndrome	158
Impact of COVID-19 Pandemic on Mechanical Reperfusion for Patients With STEMI	153
Pooled Patient-Level Analysis of Inclisiran Trials in Patients With Familial Hypercholesterolemia or Atherosclerosis	152
Cardiac Involvement in Fabry Disease	149
Global Burden of Cardiovascular Diseases and Risks Collaboration, 1990-2021	148
Recent Randomized Trials of Antithrombotic Therapy for Patients With COVID-19	147
4-Year Outcomes After Left Atrial Appendage Closure Versus Nonwarfarin Oral Anticoagulation for Atrial Fibrillation	145
Post-Stroke Cardiovascular Complications and Neurogenic Cardiac Injury	144
2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation	144
Heart Failure With Preserved Ejection Fraction	144
Percutaneous Coronary Intervention for Vulnerable Coronary Atherosclerotic Plaque	141
Medial Arterial Calcification	139
Sleep Disordered Breathing and Cardiovascular Disease	138
Short-Term Exposure to Ambient Air Pollution and Mortality From Myocardial Infarction	136
Mitochondria-Rich Extracellular Vesicles From Autologous Stem Cell–Derived Cardiomyocytes Restore Energetics of Ischemic Myocardium	136
Cardiac Rehabilitation for Patients With Heart Failure	135
2023 ACC Expert Consensus Decision Pathway on Management of Heart Failure With Preserved Ejection Fraction	135
International Impact of COVID-19 on the Diagnosis of Heart Disease	134
Dietary Inflammatory Potential and Risk of Cardiovascular Disease Among Men and Women in the U.S.	134
Predictors of Device-Related Thrombus Following Percutaneous Left Atrial Appendage Occlusion	133
Global Chronic Total Occlusion Crossing Algorithm	133
Therapeutic Potential of Ketone Bodies for Patients With Cardiovascular Disease	132
Atherosclerotic Carotid Plaque Composition and Incident Stroke and Coronary Events	129
Clonal Hematopoiesis and Risk of Progression of Heart Failure With Reduced Left Ventricular Ejection Fraction	128
Right Ventricular-Pulmonary Arterial Coupling and Afterload Reserve in Patients Undergoing Transcatheter Tricuspid Valve Repair	126
Cardiovascular Disease Projections in the United States Based on the 2020 Census Estimates	126

3-Year Outcomes of Transcatheter Mitral Valve Repair in Patients With Heart Failure	122
Effect of β-Blocker Withdrawal on Functional Capacity in Heart Failure and Preserved Ejection Fraction	121
Ultra-Processed Foods and Incident Cardiovascular Disease in the Framingham Offspring Study	120
Association of Clonal Hematopoiesis With Incident Heart Failure	120
VLDL Cholesterol Accounts for One-Half of the Risk of Myocardial Infarction Associated With apoB-Containing Lipoproteins	119
Criteria for Defining Stages of Cardiogenic Shock Severity	119
Triglycerides and Residual Atherosclerotic Risk	114
Electronic Alerts to Improve Heart Failure Therapy in Outpatient Practice	113
Empagliflozin in Patients With Heart Failure, Reduced Ejection Fraction, and Volume Overload	112
Management and Outcomes of Cardiogenic Shock in Cardiac ICUs With Versus Without Shock Teams	111
Interplay of Mineralocorticoid Receptor Antagonists and Empagliflozin in Heart Failure	111
Kidney Function and Outcomes in Patients Hospitalized With Heart Failure	111
2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease	108
Coronary In-Stent Restenosis	108
Myocardial T1 and T2 Mapping by Magnetic Resonance in Patients With Immune Checkpoint Inhibitor–Associated Myocarditis	107
Transcatheter Mitral Valve Therapy in the United States	107
Side Effect Patterns in a Crossover Trial of Statin, Placebo, and No Treatment	106
2020 ACC Expert Consensus Decision Pathway on Management of Conduction Disturbances in Patients Undergoing Transcatheter Aortic Valve Replacement	106
Three- Versus Two-Drug Therapy for Patients With Newly Diagnosed Pulmonary Arterial Hypertension	106
Mechanical Left Ventricular Unloading in Patients Undergoing Venoarterial Extracorporeal Membrane Oxygenation	106
Exercise Intolerance in Older Adults With Heart Failure With Preserved Ejection Fraction	105
2-Year Outcomes of Transcatheter Mitral Valve Replacement in Patients With Severe Symptomatic Mitral Regurgitation	103
Myocardial Bridging: Diagnosis, Functional Assessment, and Management	102
Managing Atherosclerotic Cardiovascular Risk in Young Adults	101
Incorporating Coronary Calcification Into Pre-Test Assessment of the Likelihood of Coronary Artery Disease	100
Emerging RNA Therapeutics to Lower Blood Levels of Lp(a)	100
Team-Based Care of Women With Cardiovascular Disease From Pre-Conception Through Pregnancy and Postpartum	99
Improved Risk Stratification for Ventricular Arrhythmias and Sudden Death in Patients With Nonischemic Dilated Cardiomyopathy	97
Criteria for Iron Deficiency in Patients With Heart Failure	96
Microvascular Resistance Reserve for Assessment of Coronary Microvascular Function	96
Factor XI Inhibition to Uncouple Thrombosis From Hemostasis	96
Cardiovascular Disease Risk Among Cancer Survivors	95
Cardiorespiratory Fitness and Mortality Risk Across the Spectra of Age, Race, and Sex	95
Initial Findings From the North American COVID-19 Myocardial Infarction Registry	95
Comparison of Left Bundle Branch Area Pacing and Biventricular Pacing in Candidates for Resynchronization Therapy	95
Association of Lipoprotein(a) With Atherosclerotic Plaque Progression	94
Worsening Heart Failure: Nomenclature, Epidemiology, and Future Directions	93
Effect of Pelacarsen on Lipoprotein(a) Cholesterol and Corrected Low-Density Lipoprotein Cholesterol	92
Association of Cumulative Blood Pressure With Cognitive Decline, Dementia, and Mortality	92
Phase 2 Study of Aficamten in Patients With Obstructive Hypertrophic Cardiomyopathy	91
The Increasing Role of Rhythm Control in Patients With Atrial Fibrillation	91
Cardiovascular Risk in Patients With Psoriasis	89
Eruptive Calcified Nodules as a Potential Mechanism of Acute Coronary Thrombosis and Sudden Death	88
Substrate Ablation vs Antiarrhythmic Drug Therapy for Symptomatic Ventricular Tachycardia	88
Meta-Analysis of Reversal Agents for Severe Bleeding Associated With Direct Oral Anticoagulants	87
Coronary Computed Tomographic Angiography for Complete Assessment of Coronary Artery Disease	85
Individualized Nutritional Support for Hospitalized Patients With Chronic Heart Failure	85
2021 AHA/ACC/ASE/CHEST/SAEM/SCCT/SCMR Guideline for the Evaluation and Diagnosis of Chest Pain: Executive Summary	85
Effect of Mavacamten on Echocardiographic Features in Symptomatic Patients With Obstructive Hypertrophic Cardiomyopathy	84
Finerenone Reduces New-Onset Atrial Fibrillation in Patients With Chronic Kidney Disease and Type 2 Diabetes	84
Propensity-Matched Comparison of the Ross Procedure and Prosthetic Aortic Valve Replacement in Adults	84
Independent Association of Lipoprotein(a) and Coronary Artery Calcification With Atherosclerotic Cardiovascular Risk	84
Associations of Late Adolescent or Young Adult Cardiovascular Health With Premature Cardiovascular Disease and Mortality	82
Cardiopulmonary Impact of Particulate Air Pollution in High-Risk Populations	82
National Trends in TAVR and SAVR for Patients With Severe Isolated Aortic Stenosis	82
Left Ventricular Thrombus Following Acute Myocardial Infarction	81
Micronutrient Supplementation to Reduce Cardiovascular Risk	81
High-Sensitivity C-Reactive Protein Modifies the Cardiovascular Risk of Lipoprotein(a)	81
Randomized Trial of Metoprolol in Patients With Obstructive Hypertrophic Cardiomyopathy	81
Rural-Urban Disparities in Outcomes of Myocardial Infarction, Heart Failure, and Stroke in the United States	80
Pericardial Fat and the Risk of Heart Failure	80
Increasing Participation of Women in Cardiovascular Trials	80
Lipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol	79
Prognostic Implications of Declining Hemoglobin Content in Patients Hospitalized With Acute Coronary Syndromes	79
Association of Genetic Variants With Outcomes in Patients With Nonischemic Dilated Cardiomyopathy	79
Cardiopulmonary Hemodynamics in Pulmonary Hypertension and Heart Failure	79
Acute Aortic Syndrome Revisited	78
Trends and Disparities in Cardiometabolic Health Among U.S. Adults, 1999-2018	78
International Prospective Registry of Acute Coronary Syndromes in Patients With COVID-19	78
Systolic Blood Pressure Time in Target Range and Cardiovascular Outcomes in Patients With Hypertension	77
Effect of Ejection Fraction on Clinical Outcomes in Patients Treated With Omecamtiv Mecarbil in GALACTIC-HF	77
Leptin in Leanness and Obesity	76
Diet-Derived Circulating Antioxidants and Risk of Coronary Heart Disease	76
Stress Cardiac Magnetic Resonance Myocardial Perfusion Imaging	76
Adverse Cardiovascular and Pulmonary Events Associated With Chimeric Antigen Receptor T-Cell Therapy	76
Phase 2b Randomized Trial of the Oral PCSK9 Inhibitor MK-0616	75
Moderate Aortic Stenosis in Patients With Heart Failure and Reduced Ejection Fraction	75
3-Year Outcomes After Transcatheter or Surgical Aortic Valve Replacement in Low-Risk Patients With Aortic Stenosis	75
Gerotechnology for Older Adults With Cardiovascular Diseases	74
Restoring Sinus Rhythm Reverses Cardiac Remodeling and Reduces Valvular Regurgitation in Patients With Atrial Fibrillation	74

Healthy Sleep Patterns and Risk of Incident Arrhythmias	73
Complicated Carotid Artery Plaques as a Cause of Cryptogenic Stroke	73
Incidence of Sudden Cardiac Death in the European Union	72
Cardiovascular Risk Factors Mediate the Long-Term Maternal Risk Associated With Hypertensive Disorders of Pregnancy	72
Transcatheter Replacement of Transcatheter Versus Surgically Implanted Aortic Valve Bioprostheses	71
Progression of Early Subclinical Atherosclerosis (PESA) Study	71
Hypertensive Disorders of Pregnancy and Subsequent Risk of Premature Mortality	71
Fat-Secreted Ceramides Regulate Vascular Redox State and Influence Outcomes in Patients With Cardiovascular Disease	71
Cryoballoon Ablation as Initial Treatment for Atrial Fibrillation	71
Prospective Evaluation of Autonomic Dysfunction in Post-Acute Sequela of COVID-19	71
Long-Term Outcomes of Patients Undergoing the Ross Procedure	71
Evolution and Prognostic Impact of Cardiac Damage After Aortic Valve Replacement	71
Cardiovascular Complications of Opioid Use	70
Classification of Heart Failure According to Ejection Fraction	70
Managing Patients With Short-Term Mechanical Circulatory Support	70
Advanced Management of Intermediate- and High-Risk Pulmonary Embolism	70
Targeting Higher Intraoperative Blood Pressures Does Not Reduce Adverse Cardiovascular Events Following Noncardiac Surgery	69
Etiology-Dependent Impairment of Diastolic Cardiomyocyte Calcium Homeostasis in Heart Failure With Preserved Ejection Fraction	68
Prognostic Importance of NT-proBNP and Effect of Empagliflozin in the EMPEROR-Reduced Trial	68
Changes in Plasma Renin Activity After Renal Artery Sympathetic Denervation	68
Timing of Oral P2Y12 Inhibitor Administration in Patients With Non-ST-Segment Elevation Acute Coronary Syndrome	68
Fractional Flow Reserve to Guide Treatment of Patients With Multivessel Coronary Artery Disease	67
Risk of Heart Failure in Patients With Nonalcoholic Fatty Liver Disease	67
Effect of Empagliflozin on Hemodynamics in Patients With Heart Failure and Reduced Ejection Fraction	67
Reliability of Office, Home, and Ambulatory Blood Pressure Measurements and Correlation With Left Ventricular Mass	67
2022 ACC Expert Consensus Decision Pathway on the Evaluation and Disposition of Acute Chest Pain in the Emergency Department	67
Dapagliflozin in Patients Recently Hospitalized With Heart Failure and Mildly Reduced or Preserved Ejection Fraction	66
Consumption of Olive Oil and Risk of Total and Cause-Specific Mortality Among U.S. Adults	66
Antithrombotic Therapy After Left Atrial Appendage Occlusion in Patients With Atrial Fibrillation	66
Randomized Trial of Ivabradine in Patients With Hyperadrenergic Postural Orthostatic Tachycardia Syndrome	66
Glycated Hemoglobin and Subclinical Atherosclerosis in People Without Diabetes	65
Management of Patients With Giant Cell Myocarditis	65
Exercise-Induced Cardiovascular Adaptations and Approach to Exercise and Cardiovascular Disease	65
Phenotypic Expression and Outcomes in Individuals With Rare Genetic Variants of Hypertrophic Cardiomyopathy	65
Lifespan Perspective on Congenital Heart Disease Research	65
Comparative Study of Oral Anticoagulation in Left Ventricular Thrombi (No-LVT Trial)	65
Aspirin for Primary Prevention of Cardiovascular Events in Relation to Lipoprotein(a) Genotypes	65
Trends and Outcomes of Left Ventricular Assist Device Therapy	64
Myocardial Fibrosis as a Predictor of Sudden Death in Patients With Coronary Artery Disease	64
Angiotensin-Neprilysin Inhibition in Patients With Mildly Reduced or Preserved Ejection Fraction and Worsening Heart Failure	63
High-Intensity Statin Use Among Patients With Atherosclerosis in the U.S.	63
P2Y12 Inhibitor Monotherapy or Dual Antiplatelet Therapy After Complex Percutaneous Coronary Interventions	63
P2Y12 Inhibitor or Aspirin Monotherapy for Secondary Prevention of Coronary Events	63
Modulation of Cardiac Arrhythmogenesis by Epicardial Adipose Tissue	63
New and Emerging Therapies for Reduction of LDL-Cholesterol and Apolipoprotein B	63
4-Year Outcomes of Patients With Aortic Stenosis in the Evolut Low Risk Trial	63
Intravascular Imaging During Percutaneous Coronary Intervention	62
Does Patient-Physician Gender Concordance Influence Patient Perceptions or Outcomes?	62
Pooled Analysis of PFO Occluder Device Trials in Patients With PFO and Migraine	61
Coronary Atherosclerotic Plaque Regression	61
Direct Oral Anticoagulants vs Vitamin K Antagonists in Patients With Antiphospholipid Syndromes	60
Deep Learning Electrocardiographic Analysis for Detection of Left-Sided Valvular Heart Disease	60
Evaluation and Management of Patients With Stable Angina: Beyond the Ischemia Paradigm	59
Exercise for Primary and Secondary Prevention of Cardiovascular Disease	59
Prevention of Pathological Atrial Remodeling and Atrial Fibrillation	59
Supplemental Vitamins and Minerals for Cardiovascular Disease Prevention and Treatment	59
Sodium Glucose Cotransporter-2 Inhibition for Acute Myocardial Infarction	59
Socioeconomic Determinants of Health and Cardiovascular Outcomes in Women	58
Elevated Remnant Cholesterol Reclassifies Risk of Ischemic Heart Disease and Myocardial Infarction	58
Transcatheter Pulmonary Valve Replacement With the Sapien Prosthesis	58
Empagliflozin Improves Cardiovascular and Renal Outcomes in Heart Failure Irrespective of Systolic Blood Pressure	58
A Score to Assess Mortality After Percutaneous Mitral Valve Repair	57
Pathophysiology of the Lymphatic System in Patients With Heart Failure	57
The Evolution of the Quintuple Aim	57
Left Atrial Appendage Closure Versus Oral Anticoagulants in Atrial Fibrillation	57
Association of Hypertensive Disorders of Pregnancy With Left Ventricular Remodeling Later in Life	57
In-Hospital Initiation of Sodium-Glucose Cotransporter-2 Inhibitors for Heart Failure With Reduced Ejection Fraction	57
Evolution of Late Right Heart Failure With Left Ventricular Assist Devices and Association With Outcomes	57
Cardiovascular and Kidney Outcomes Across the Glycemic Spectrum	57
Inflammatory Bowel Disease and Atherosclerotic Cardiovascular Disease	57
Canadian Spontaneous Coronary Artery Dissection Cohort Study	56
Elevated Lipoprotein(a) and Risk of Atrial Fibrillation	56
Impact of Peridevice Leak on 5-Year Outcomes After Left Atrial Appendage Closure	56
Current Status and Future Prospects of Transcatheter Mitral Valve Replacement	56
Basic and Translational Research in Cardiac Repair and Regeneration	56
Association of Left Atrial Structure and Function With Heart Failure in Older Adults	56
Evaluating Medical Therapy for Calcific Aortic Stenosis	56
Survival Following Alcohol Septal Ablation or Septal Myectomy for Patients With Obstructive Hypertrophic Cardiomyopathy	56
Chronic Thromboembolic Pulmonary Hypertension	56
Device Therapy in Chronic Heart Failure	56
COVID-19 in Adults With Congenital Heart Disease	56
Patient Characteristics and Clinical Outcomes of Type 1 Versus Type 2 Myocardial Infarction	56
Remnant Cholesterol and Atherosclerotic Cardiovascular Disease Risk	55
Pre-Pregnancy Hypertension Among Women in Rural and Urban Areas of the United States	54
2-Year Outcomes After Transcatheter Versus Surgical Aortic Valve Replacement in Low-Risk Patients	54
Low-Dose Colchicine for Secondary Prevention of Coronary Artery Disease	54
Management of Women With Congenital or Inherited Cardiovascular Disease From Pre-Conception Through Pregnancy and Postpartum	54
Vitamin D, Calcium Supplements, and Implications for Cardiovascular Health	53
Gender Differences in Takotsubo Syndrome	53
Rural-Urban Disparities	53
Feasibility and Potential Impact of Heart Transplantation From Adult Donors After Circulatory Death	53
Severe Mental Illness and Cardiovascular Disease	53
Effects of Canagliflozin on Amino-Terminal Pro–B-Type Natriuretic Peptide	53
Long-Term Cardiovascular Outcomes in Systemic Lupus Erythematosus	52
Effects of Experimental Sleep Restriction on Energy Intake, Energy Expenditure, and Visceral Obesity	52